Research · Randomized controlled trial
Docosahexaenoic acid (DHA) supplementation in atopic eczema: a randomized, double-blind, controlled trial
What it found
A small pilot trial: DHA reduced SCORAD severity (37.0→28.5) more than control; promising but underpowered and not yet confirmed in larger trials.
- Design
- Randomized controlled trial
- Year
- 2008
- Sample size
- 53
- Population
- adults aged 18–40 with atopic eczema (21 DHA vs 23 control analyzed)
- Intervention
- oral DHA 5.4 g/day vs an isoenergetic saturated-fat control for 8 weeks
- Outcome
- SCORAD severity index
- Journal
- British Journal of Dermatology
Citation last checked 2026-06-21.